Multidisciplinary Task Force: Increasing Early Intervention and Optimizing Management in Psoriatic Arthritis

Psoriatic arthritis is a chronic inflammatory disorder affecting 20% of patients with psoriasis, causing joint pain, stiffness, swelling, and fatigue that significantly impact quality of life. Early diagnosis is critical, as many patients are not identified until later stages when irreversible damage has occurred. This Multidisciplinary Task Force explores strategies for early intervention, the use of novel imaging and biomarkers, and optimizing treatment selection and sequencing.

Featuring expert insights from Christopher Ritchlin, MD, MPH; Jennifer Soung, MD; Archie Franklin, MBA; Saba Mohiuddin, PharmD, BCACP; and Melodie S. Young, MSN, A/GNP-C, this discussion highlights the latest advancements in psoriatic arthritis management and emerging therapies.

STATEMENT OF NEED

Psoriatic arthritis is a chronic inflammatory disorder that affects approximately 20% of patients with psoriasis. Symptoms, which include joint pain, stiffness, swelling, tendon and ligament tenderness, silvery or gray scaly patches, nail discoloration, and fatigue, usually manifest in flares and greatly impact patients’ quality of life (Kimak et al, 2023; Cleveland Clinic, 2023). Many patients are not diagnosed with psoriatic arthritis until later stages when lesions are irreversible. Screening for risk factors and early symptoms, in addition to incorporating novel imaging modalities and biomarkers, is crucial to making an early diagnosis and administering treatment that can prevent or delay the disease (Kimak et al, 2023). With numerous novel therapies in development, it is critical for members of the multidisciplinary team to remain up to date on emerging data in order to tailor treatment selection and sequencing. This Multidisciplinary Task Force explores strategies for increasing early intervention and optimizing management of psoriatic arthritis. It features perspectives from Christopher Ritchlin, MD, MPH, Professor and Chief of the Division of Allergy, Immunology and Rheumatology at the University of Rochester Medical Center; Jennifer Soung, MD, Director of Clinical Research at Southern California Dermatology and Clinical Faculty at Harbor University of California, Los Angeles; Archie Franklin, MBA, Patient Advocate and Volunteer for the National Psoriasis Foundation; Saba Mohiuddin, PharmD, BCACP, Clinical Pharmacist at KabaFusion; and Melodie S. Young, MSN, A/GNP-C, Nurse Practitioner at Mindful Dermatology and Modern Research Associates. 

TARGET AUDIENCE

Rheumatologists, dermatologists, primary care physicians, nurse practitioners, physician assistants/associates, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with psoriatic arthritis (PsA)

Upon completion of this activity, participants should be able to:

• Utilize knowledge of defining features, screening tools, and biomarkers to provide timely and accurate diagnosis of psoriatic arthritis
• Evaluate the safety and efficacy of novel psoriatic arthritis therapies
• Appraise strategies for tailoring treatment selection and sequencing to individual patients with psoriatic arthritis
• Assess methods to improve supportive care for patients with psoriatic arthritis

PROVIDED BY

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 3/4/26. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development

A maximum of 1.25 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 1.25 ANCC contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.25 ANCC contact hours. 

Continuing Pharmacy Education

i3 Health has approved this knowledge-based activity for 1.25 ACPE CE hours. The Universal Activity Number for this activity is JA0008128-0000-25-016-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion. 

i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Christopher Ritchlin, MD, MPH, discloses that he has served on an advisory board or panel for Janssen and Novartis; that he has served as a consultant for AbbVie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Solarea, and UCB; and that he has received grants/research support from Janssen, Novartis, and UCB.  

Jennifer Soung, MD, dislcoses that she has served on an advisory board or panel for AbbVie, Amgen, Coval Biopharma, Lilly; that she has served on a speaker's bureau for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Regeneron/Sanofi, and UCB; that she has served as a consultant for Arcutis, Bristol Myers Squibb, Novartis, Pfizer, and Regeneron/Sanofi; and that she has received grants/research support from AbbVie, Amgen, Arcutis, Aslan, Dermavant, Janssen, KoBio Labs, Lilly, Novartis, Pfizer, Regeneron/Sanofi, and UCB.

Archie Franklin, MBA, has no relevant financial relationships to disclose. 

Saba Mohiuddin, PharmD, BCACP, has no relevant financial relationships to disclose. 

Melodie S. Young, MSN, A/GNP-C, discloses that she has served on an advisory board or panel for Abbvie, Amgen, Arcutis, Dermavant, LilIy, Novartis, Takeda, and UCB; that she has served on a speaker's bureau for Amgen, Dermavant, Johnson & Johnson, Leo, Lilly, Sun, and UCB; and that she has received grants/research support from AbbVie, Alumis, Amgen, Aslan, Boehringer Ingelheim, Caratherapeutics, Incyte, Janssen, Lilly, Pfizer, Takeda, and UCB.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME/NCPD/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by educational funding provided by Amgen.